Source: UNIVERSITY OF FLORIDA submitted to NRP
INHIBITION OF THE GUT MICROBIAL METABOLITE TRIMETHYLAMINE N-OXIDE (TMAO) USING ORANGE PEEL TO PREVENT CARDIOVASCULAR DISEASE
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
COMPLETE
Funding Source
Reporting Frequency
Annual
Accession No.
1018535
Grant No.
2019-67017-29246
Cumulative Award Amt.
$494,325.00
Proposal No.
2018-07925
Multistate No.
(N/A)
Project Start Date
Apr 1, 2019
Project End Date
Mar 31, 2025
Grant Year
2019
Program Code
[A1341]- Food Safety, Nutrition, and Health: Function and Efficacy of Nutrients
Recipient Organization
UNIVERSITY OF FLORIDA
G022 MCCARTY HALL
GAINESVILLE,FL 32611
Performing Department
Food Science & Human Nutrition
Non Technical Summary
Recent studies indicate gut microbiota is involved in development of Cardiovascular Disease. Gut microbiota transform choline and carnitine, commonly found in meat or egg yolk, to trimethylamine (TMA), which can then be converted into trimethylamineN-oxide (TMAO) by hepatic enzymes. TMAO accelerates atherosclerosis and is associated with major adverse cardiac events. There is solid reasoning for investigating orange peel to modulate gut microbiota subsequently inhibiting TMAO formation: 1) our preliminary study showed orange peel can inhibit TMAO formationin vivoviaalteration of gut microbiota as well as inhibit a microbial carnitine-specific TMA enzyme to prevent carnitine transforming into TMAin vitro. 2) Approximately five million tons of orange peel are generated annually in the US; 3) Natural orange peel extracts are considered substances Generally Recognized As Safe (GRAS) by the FDA; 4) Increased usage of orange peel directed at improving heart health could potentially provide additional economic returns benefiting US agriculture and food systems. The hypotheses of this project are orange peel can effectively prevent development of atherosclerosis via modifying gut microbiota, and orange peel contains bioactive components that interfere with activity of carnitine-specific TMA enzymes. To test these hypotheses, our interdisciplinary team will combine animal studies and natural products chemistry within vitroenzyme assays to assess pathways associated with orange peel consumption, TMA/TMAO metabolism and prevention of atherosclerosis as well as identify TMA inhibitors, respectively.
Animal Health Component
(N/A)
Research Effort Categories
Basic
100%
Applied
(N/A)
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
70109201010100%
Knowledge Area
701 - Nutrient Composition of Food;

Subject Of Investigation
0920 - Orange;

Field Of Science
1010 - Nutrition and metabolism;
Goals / Objectives
Our long-term goal is to improve gut health using orange peel to prevent cardiovascular disease and promote heart health. Our preliminary study has demonstrated the effects of orange peel on inhibiting TMAO formation via remodeling gut microbiota, and several additional studies have indicated antimicrobial effects of orange peel as well. Therefore, a solid foundation has been established for investigating orange peel for its capability to adjust the gut microbiome and inhibit TMAO formation. The overall objectives of this project are to adjust gut microbiota with orange peel, which in turn will inhibit TMA/TMAO formation and ultimately, effectively prevent atherosclerosis, as well as to identify the bioactive components of orange peel that influence the gut microbiome function of converting food ingredients (choline, carnitine etc.) into trimethylamine (TMA).
Project Methods
1.1 Short-term treatment: Ten-week-old male and female C57BL/6J mice will be used to examine the capability of gut microbiota to generate TMA and TMAO following carnitine intake, as well as the inhibitory efficacy of orange peel compared with the positive control, resveratrol. Mice will be divided into four groups (n=16 in each group, 8 of each gender): (1) regular diet (Teklad 2018 containing 0.12% choline) (2) carnitine-supplemented diet (Teklad 2018+1.3% carnitine in the drinking water, wt/v) (3) carnitine-supplemented diet plus orange peel (4) carnitine-supplemented diet plus resveratrol. The orange peel powder will be mixed with the regular diet. The concentration of orange peel used in the diet will be 5 mg/g diet. The resveratrol concentration used will be the same as that in the reference (4 mg/g diet) . After two weeks, mice will be scarified and tissues/samples (liver, kidney, plasma and urine) will be collected to measure choline, L-carnitine, TMAO and TMA levels using LC-MS/MS. 1.2 Long-term treatment: Four-week-old male and female C57BL/6 Apoe-/- mice (after weaning) will be used. C57BL/6 Apoe-/- mice are prone to develop atherosclerosis, and are a suitable model to study cardiovascular disease. Mice will be divided into six groups (n=16 in each group, 8 of each gender): (1) regular diet (Teklad 2018 containing 0.12% choline) (2) carnitine-supplemented diet (3) carnitine-supplemented diet plus low dose of orange peel (4) carnitine-supplemented diet plus high dose of orange peel (5) regular diet plus low dose of orange peel (6) regular diet plus high dose of orange peel. Carnitine-supplemented diet is the regular diet reformulated with 1.3% (wt/vol) carnitine in the drinking water. Orange peel will be administered at a dose of 5 mg/g diet constituting the low dose, and 10 mg/g constituting the high dose. All mice will have free access to food and water. Mice will be sacrificed after 16 weeks of receiving the different diets. Blood, heart and cecum will be collected for TMA/TMAO analysis, aortic lesion quantification, and microbiota analysis, respectively. Toxicity to chronic exposure of orange peel will be evaluated via renal and liver functions. Organs such as liver, spleen, kidney and intestine will be harvested for histopathology. Liver tissues will be also used for studying effects of orange peel on hepatic Flavin monooxyegenase 3. 1.3 Carnitine, TMA, and TMAO quantification: Stable isotopes (d9-TMA, d9-TMAO d9-choline and d3-carnitine) dilution analysis with UHPLC-tandem mass spectrometry (LC-MS/MS) will be used for quantification of TMA, TMAO, carnitine and choline in the blood and the tissues. LC/MS/MS will be performed on an Ultimate 3000 LC system coupled to a TSQ Quantiva triple quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) using hydrophilic interaction chromatography (HILIC). The analytes will be separated using a Thermo scientific Accucore HILIC column (2.1 × 100 mm, particle size 2.6 μm) at a column temperature of 30°C, using a gradient elution with acetonitrile (eluent A) and 15 mM ammonium formate (pH 3.5) (eluent B). The gradient will be as follows: 0-4 min 10-40% B and 4-6 min 40% B. The flow rate will be 0.4 mL/min. The MS/MS detection will be operated using selective reaction monitoring (SRM) mode. The precursor and product ions: m/z 60→44 for TMA, m/z 69→49 for d9-TMA, m/z 76→58 for TMAO, m/z 85→66 for d9-TMAO, m/z 104→60 for choline, m/z 113→69 for d9-choline, m/z 162→103 for carnitine and m/z 165→103 for d3-carnitine.2.1 Preparation of orange peel extracts: Sequential extraction will be applied which will result in four different extracts. 100g of dried ground orange peel (100g dry weight) will be extracted with n-pentane (3×500mL). Next the remainder will be extracted sequentially, first using ethyl acetate (3×500mL), then methanol (3×500mL) and finally water (3×500mL). All organic solvent and water will be removed using rotary evaporation and then freeze dried. These extracts will be applied to the carnitine-specific TMA lyase bio-model for analysis of orange peel TMA inhibitors. 2.2 Carnitine-specific TMA lyase (cntA/B) bio-model: Amplifier cntA and cntB genes will be inserted into the plasmid pCOLADDuet-1 (Novagen), and co-expression of cntA and cntB will be obtained through insertion under the BamHI/HindIII and the NdeI/KpnI sites, respectively. The plasmid then will be transformed into the host E. coli BL21(DE3) pLysS using heat shock transformation. E.coli will be incubated at 37°C and will be grown to an OD600 of 0.5 and isoprophyl β-D-1-thiogalactopyranoside (IPTG) will be added at a concentration of 0.2mM to induce protein over-expression. Enzymes will be purified using a His-tag affinity column. The cell free enzyme system will then be used for bio-guided purification. This model has been validated in the preliminary study. 2.3 Purification and Identification of TMA inhibitors: The five orange peel extracts (from 2.1) will be applied to the carnitine-specific TMA lyase model, separately. The extract/s with high inhibitory efficacy will be analyzed for effective components using the bio-guided enzyme model and will be further fractionated using gel permeation chromatography (Diaion HP-20, Sephadex LH 20) or fast centrifugal partitioning chromatography (FCPC), respectively. The sub-fractions obtained will again be evaluated for their TMA inhibitory activity in the carnitine-specific TMA lyase bio-model (from 2.2) and the most active fractions will be further separated by means of Medium pressure-LC and High pressure-LC techniques. The compounds evaluated to have the highest activities will be isolated in preparative amounts by preparative HPLC and identified using LC-MS/MS, LC-TOF-MS, as well as by 1D- and 2D-NMR spectroscopy (500 MHz spectrometer with cryo probe), and, if suitable, by synthetic experiments. The TMA will be quantified using the MRM model (60->44) in LC-MS/MS). The natural concentrations of these effective compounds in orange peel will be quantified using LC-MS/MS. The TMA inhibitors will be used to perform dose/activity studies in the carnitine-specific TMA lyase bio-model and to determine the corresponding IC50 values.

Progress 04/01/23 to 03/31/24

Outputs
Target Audience:The target audience for this project remains largely unchanged compared to the previous year, continuing to focus on key groups such as the citrus industry, scientists working in nutrition and natural products chemistry, and the general public. As orange peel is a major by-product of orange juice processing, our work to explore its potential use in disease prevention and human health improvement remains relevant and valuable to these groups. In the past, orange peel was primarily used as cattle feed, but our findings highlight its potential to benefit the citrus industry economically by offering new applications in food systems for health improvement. This year, however, our reach has expanded. The publication of our work, along with a news releaseand presentations, has allowed us to connect with a broader audience. Following the news release of our research, we received inquiries from the general public, reflecting growing interest in the health benefits of orange peel and its compounds. Additionally, the citrus industry has shown increased interest, hoping to find pathways to further support and extend this work. We continue to engage citrus growers, processors, packers, and food ingredient companies, explaining how orange peel can improve heart health and discussing the specific compounds responsible for these effects. Feedback from stakeholders has been positive, with growers eager to understand how these findings can be applied to increase economic returns and ingredient companies excited about developing new products using orange peel byproducts. We have shared our results at scientific meetings and industry extension meetings, including a presentation at the ACS meeting in 2023, and another one in August 2024 and a presentaion at the ICBC meeting in September, 2024. These efforts ensure that our findings continue to benefit and engage a wide audience across both scientific and industry sectors. Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?This year, we continued to provide valuable training and professional development to our postdoctoral researchers and graduate students through this project. Both postdocs from Dr. Wang's and Dr. Yokoyama's labs received ongoing support to strengthen their writing and presentation skills. Each had the opportunity to present their research at scientific meetings, enhancing their professional experience.In Dr. Wang's lab, the postdoc collaborated with thepostdoc in Dr. Yokoyama's lab on a publication that garnered significant public attention, further highlighting their research impact. Both postdocs have successfully secured positions--one in academia and the other in industry--demonstrating the effectiveness of the training provided.Additionally, the graduate student in Dr. Niu's lab continues to receive training in data analytics and processing, building expertise in data science, which is essential for their future career development. How have the results been disseminated to communities of interest?The results of this project have been disseminated to communities of interest through multiple channels. We published a paper that includes the key findings reported in the accomplishments section, specifically detailing how orange peel extracts decrease TMA and TMAO levels by inhibiting enzyme activities and identifying the effective compounds responsible for these effects. This publication received significant public attention following a news release that explained the research in layman's terms, making the findings accessible to a broader audience.In addition to the publication, we presented these results at various scientific meetings, where we engaged with researchers and industry professionals, further disseminating our findings and fostering discussions on the potential applications of orange peel in promoting heart health. What do you plan to do during the next reporting period to accomplish the goals?During the next reporting period, as our project concludes in March 2025, we will focus on wrapping up our remaining studies. All the objectives and commitments outlined in the original proposal have been completed, but we still have unpublished data, specifically related to the metabolism of the effective compounds in orange peel. We plan to compile these findings and publish them in a separate paper. ?Another key step will be disseminating our final results. I will be presenting our findings at various scientific meetings and events to ensure our work reaches a wide audience. Additionally, we will ensure that all results from our students' research are communicated effectively to stakeholders, including the citrus industry, scientists, and other relevant parties. This will help maximize the impact of our project and ensure that the findings are well-integrated into future research and industry applications.

Impacts
What was accomplished under these goals? Under our long-term goal of improving gut health through the use of orange peel to prevent cardiovascular disease and promote heart health, we made significant progress in understanding the mechanisms behind the reduction of TMA (trimethylamine) and TMAO (trimethylamine-N-oxide) levels. Our previous results demonstrated that both polar and non-polar extracts of orange peel effectively decreased TMA and TMAO levels in plasma and urine. However, 16S rRNA sequencing did not reveal significant changes in gut microbiota composition, suggesting an alternate mechanism responsible for the reduction in TMA and TMAO levels. 1. Enzyme Inhibition Model:To explore this potential mechanism, we set up a carnitine monooxygenase/reductase enzyme model to test if orange peel extracts inhibit enzyme activity, thereby reducing TMA levels. We applied carnitine alone, carnitine with orange peel polar extract, carnitine with orange peel non-polar extract, and the positive control berberine to the enzyme model. Our findings revealed that the orange peel polar extract significantly inhibited carnitine enzyme activity compared to the non-polar extract, leading to a notable reduction in TMA levels. 2. Metabolomics Profiling and Bioactive Component Identification:We applied untargeted metabolomics to profile the orange peel extracts and identified individual compounds with inhibition activity. Among the compounds tested, feruloylputrescine was identified as significantly inhibiting carnitine enzyme activity and decreasing TMA levels, even more effectively than the positive control berberine. 3. In Vivo Validation:To validate the activity of feruloylputrescine in vivo, we conducted a study in mice. We compared the effects of pure feruloylputrescine, orange peel polar extract, orange peel non-polar extract, and a control group treated with carnitine. The results confirmed that feruloylputrescine significantly decreased TMA and TMAO formation in the in vivo model, further solidifying its potential as a key bioactive compound in the prevention of atherosclerosis through gut microbiome modulation.

Publications

  • Type: Journal Articles Status: Published Year Published: 2024 Citation: Lee, H., Koh, GY., Lee, H., Alves, P., Yokohama, W., Wang, Y. Discovery of a novel bioactive compound in orange peel polar fraction on the inhibition of thrimethylamine and trimethyl N-Oxide through metabolomics approaches and in vitro and in vivo assays: feruloylputrescine inhibits trimethylamine via suppressing cntA/B enzyme. J. Agric. Food Chem., 2024, 72, 14, 7870-7881
  • Type: Journal Articles Status: Published Year Published: 2023 Citation: Lee, H., Xin, L., An, J., Wang, Y. Identification of polymethoxyflavones (PMFS) from orange peel and their inhibitory effects on the formation of thrimethylamine (TMA) and thimethylamine-N-oxide (TMAO) using cntA/B and cutC/D enzymes and molecular docking. J. Agric. Food Chem. 2023, 71, 43, 16114-16124
  • Type: Conference Papers and Presentations Status: Accepted Year Published: 2023 Citation: Wang, Y., Lee, H. The effects of polymethoxyflavones (PMFs) from orange peel on the inhibition of trimethylamine (TMA) and trimethylamine-N-oxide (TMAO) producing enzymes and TMA/TMAO production: in vitro study and docking analysis. 266th American Chemical Society National Meeting & Exposition, San Francisco, 2023


Progress 04/01/22 to 03/31/23

Outputs
Target Audience:The target audience of this project in the past year was citrus industry, scientists working in theareas of nutrition and natural products chemistry as well as the general public. Orange peel is the major by-productgenerated during orange juice processing. In the past, the main use of orange peel is the cattle feed. If the orange peel can be used in the food system to prevent diseases and improve human health, it could largely benefit the entire citrus industry economically. Therefore, we communicated our findings with entities such as citrus growers, processers, packers and food ingredient company using citrus peel as ingredients. We explained to them the potential of using orange peel to improve heart health and indicated the potential compounds in the peel showing the health benefits as well as the mechanisms. We are preparing an extension article for the citrus industry and hope could be published by the end of the year. Meanwhile, we also presented our results at the scientific meetings to disseminate our findings such as what compounds in the peel would prevent the transformation from carnitine to TMAO.One presentation will be given at the upcoming ACS meeting in August 2023. The comments we received from the stakeholders so far were very positive. The growers would like to know more how the results could be used by the industry and increase economic returns. The ingredient companies are excited, and they would like to consider how to develop new products using the orange peel left from juice processing. Changes/Problems:Originally, we didn't plan to test more natural compoundsin the cntA/B and cutC/D models. However, the results from our planned studies were so interesting, so we hope we could test more before the project ends. In addition, the animal study at USDA-ARS were delayed previously due to the pandemic closure then lack of the facility staff. It has been gradually coming back and we hope we could complete all planned animal studies before the project ends. What opportunities for training and professional development has the project provided?The new hired postdoc by Dr. Wang's group in the area of natural products chemistry started her work in the beginning of year 2022. She used this opportunity to learn compound isolation and identification as well as molecular docking. She is also trained to use machine learn models to predict bioactivity based on chemical structures. In addition, she learnt how to write scientific publications and how to give scientific presentations. The postdoc. hired by Dr. Yokoyama's group focused on the training of developing animal models and bioinformatics. She also has been trained for grant writing. We hope the training provided by this project could well prepared the trainee for the future academic jobs. In addition, Dr. Niu enrolled a graduate student who has been trained in the data science and data processing. How have the results been disseminated to communities of interest? We submitted one publication based on our cntA/B and cutC/D results. Based on all our current data, we are preparing another two publications.One focused on our animal study which provide a novel perspective on how orange peel inhibit TMAO and TMAO formation other than just altering the composition of gut microbiota. The one focus on the relationship of chemical structures and inhibition efficacy. These scientific publications will possess a large number of readers from academia and industry. We will organize our findings into an extension article which much more focuses on stakeholders. Additionally, some of the results have been and will be presented at the educational workshop and scientific conferences. What do you plan to do during the next reporting period to accomplish the goals?1. Complete the paper writing for the animal study which focus on the mechanisms of how orange peel inhibit TMAO and TMA formation. 2. Apply more natural compounds onto cntA/B and cutC/D models to have a data repositoryon structural-activity relationship particularly to complete the machine learning prediction models to predict inhibition efficacy of TMAO and TMA formation in the future just based on chemical structures. 3. Complete the testing such as TMAO, TMA, carnitine levels etc. in the biosamples from theApoe−/−mice study.

Impacts
What was accomplished under these goals? As known, there is a lot of fibers in the orange peel which can alter the gut microbiota composition significantly then leading to the decrease of TMA and TMAO. However, in our study, we focused on more other polyphenol compounds and their function other than just changing the gut microbiota composition. In our study, we have five groups of mice: 1) treated with standard chow; 2) treated with standard chow plus carnitine; 3) treated with standard chow+ carnitine +orange peel polar fraction 4) treated with standard chow+ carnitine +orange peel non-polar fraction 5) treated with standard chow+ carnitine +antibiotics cocktail. As a result, we didn't observed a significant gut microbiota composition change between groups treated with polar or non-polar orange peel extracts and group just treated with carnitine. However, we did observe TMAO and TMA levels decreased within groups of treated with orange peel extracts indicating other mechanisms were presented. In fact, cnt A/M enzyme activity has been significantly inhibited by orange peel extracts indicating inhibiting enzyme activity is a potential way to decrease TMAO level. We completed the study of testing 12 PMFs to inhibit cntA/B, cutC/D and FMO3 activities. We used molecular docking to analyze the relationship between chemical structures and inhibition efficacy indicating the key structural characteristics corresponding to each individual enzyme. The work has been submitted to Journal of Agriculture and Food Chemistry and it is under review now. Apoe−/−mice studies were conducted. Four treatments were performed: 1) treated with standard chow; 2) treated with standard chow plus carnitine; 3) treated with standard chow+ carnitine +low orange peel extract 4) treated with standard chow+ carnitine +high orange peel extract. So far, the body weight, food and water intake were monitored and didn't see significant changes among treatments. The further analyses will be done in the following months.

Publications

  • Type: Journal Articles Status: Published Year Published: 2022 Citation: Koh, G.Y., and Wang, Y. (2022). Implications of type 1 and type 2 taste receptors on obesity-induced inflammation. J. Food Bioact. 20:2-10
  • Type: Journal Articles Status: Under Review Year Published: 2023 Citation: Lee, H., Liu, X., An, J., Wang, Y. Identification of polymethoxyflavones (PMFs) from orange peel and their inhibitory effects on the formation of trimethylamine (TMA) and trimethylamine-N-oxide(TMAO) using cntA/B and cutC/D enzymes and molecular docking. Submitted to Journal of Agricultural and Food Chemistry in July 2023 and now it is under review.
  • Type: Conference Papers and Presentations Status: Other Year Published: 2023 Citation: Wang, Y., Lee, H., et al. In vitro study of polymethoxyflavones (PMFs) from orange peel for their potential to inhibit trimethylamine (TMA) and trimethylamine-N-oxide (TMAO)-producing enzymes and reduce TMA/TMAO production. Division of Agricultural and Food Chemistry, Sustainable Agriceuticals, ACS Fall 2023.


Progress 04/01/21 to 03/31/22

Outputs
Target Audience:The target audience of this project in the past year wascitrus industry andthe general public. The citrus industry is actually a big audience group containing various entities such as citrus growers, processers, packers and food ingredient company using citrus peel as ingredients.We have presented the results and findings from this work at the citrus extension workshop. We talked with these stakeholders. We explained to them the potential of using orange peel to improve heart health and indicated the potential compounds in the peel showing the health benefits. The comments we received from the stakeholders were very positive. The growers would like to know more if the similar compounds can be identified in the fruits. The processers are excited in addition to juice products, there might be a potential to use the juice processing by-products (orange peel).All entities expected to see more results from this study. Changes/Problems: The co-PI Dr. Wallace Yokoyama who mainly is in charge of the animal study locates in USDA-ARS California. In the past year, the entire ARS animal facility in California could not be fully open. We start to resume the animal study in May 2022. The animal study was hugely delayed.Therefore, it could take longer than we plannedto complete the entire study, and we may need another year extension. What opportunities for training and professional development has the project provided?After the first postdoc. left for an academic job, we hired another postdoc. in the beginning ofyear 2022 to continue this project. We use this position to train postdoc. in the areas of biochemistry and analytical chemistry as well as we train people to write scientific publications and presentation skills.We hope the training provided by this project could well prepared the trainee for the future academic jobs.In addition, the Co-PI enrolled a graduate student who has been trained in the data science and data processing. How have the results been disseminated to communities of interest? Based on the data we have already, we are preparing two publications.One focuses on the animal study and bacterial enzyme study, and the other one focuses on compound identification and the study of structure-activity. These scientific publications will possess a large number of readers from academia and industry. Additionally, some of the results have been presented at the educational workshop. We expect to give more presentations at the scientific meetings for disseminating information after our papers are published. What do you plan to do during the next reporting period to accomplish the goals? Start the study of usingApoe−/−miceto test the orange peel extract and effective compounds from the orange peel. Test the purified compounds from the bioactivity-guided fractionation of orange peel inC57BL/6mice as well as test these purified compounds using liver enzyme FMO3 which can transform TMA into TMAO.In this way, we could understand the mechanisms of inhibiting TMAO formation using these compounds from orange peel. Study the structure-activity relationship using molecular docking

Impacts
What was accomplished under these goals? Here are the accomplishments we have acchived in the past year In addition to develop a carnitine enzyme (CntA/B) as we proposed in proposal, we developed a choline enzyme(Cut C/D) as well. Because during our study, we realizedthat some bioactive compounds may work differently on these two enzymes, even though they can both transform diet ingredients into TMA. We used these two enzymes to conduct bioactivity-guided compound isolation and identification in the orange peel extract. The inhibition efficacy of each individual compound has been tested and compared with positive control. The structure-activity are under studied. In total of 12 compounds have been identified from orange peel, which may inhibit the transformation from carnitine/choline to TMA.

Publications


    Progress 04/01/20 to 03/31/21

    Outputs
    Target Audience: Target audience of this project is citrus industry and the general public. Florida is the largest citrus producer in the U.S., with nearly 95% of Florida oranges used for juice. The current juice recovery rate is approximately fifty percent with the remaining peel byproduct typically going to cattle feed. Expanding the use of orange peel to benefit human health is a solid way to promote sustainability of US agriculture. Plus, this could potentially provide greater economic returns to the citrusindustry. These scientific findings will be published in top journals such as Molecular Nutrition & Food Research, which possess a large number of readers from academia and industry. Additionally, these findings will be presented at scientific meetings for educating both industry and the public. In the past year, we have reached out citrus growers and people working in the citrus industry and provided information of how and why citrus peel could be used to adjust gut microbiota and improve heart health.An educational presentation was given at a citrus workshop.The feedback we received was very positive and many growers would like to contribute their fruits for the research study.? Changes/Problems:It was difficult for us to run animal studies during the pandemic. The co-PI Dr. Wallace Yokoyama who mainly is in charge of the animal study locates in USDA-ARS California. In the past year, the entire ARS animal facility in California could not be open. We still can't use the animal facility till maybe the end of April. Therefore, we conducted some animal studies at University of Florida where the PI Dr. Wang locates.Due to the issues above, the progress of both animal and analytical studies was delayed.In addition, the postdoc who we hired for conducting both the molecular biology and chemistry work has got a faculty job and we need to hire someone new to continue this work. Therefore, it could take a while to resume this project. What opportunities for training and professional development has the project provided?A postdoctoral associate was hired for this project.This project needs analytical and molecular biology techniques. It is a good chance for the postdoc. trainee to learn both. In addition, training for the presentation and writing skills were provided as well. This postdoc. submitted one abstract to a nutrition meeting but due to COVID-19, she didn't have a chance to present.However, she gave an educational presentation to the citrus industry including growers, processers and academic scientists working in citrus field. This postdoc. was hired in August, 2019, and via one and half year training, she successfully obtained a faculty position in a university in Texas.? How have the results been disseminated to communities of interest?These scientific findings will be published in top journals such as Molecular Nutrition & Food Research, which possess a large number of readers from academia and industry. Till now, we are still in the process of collectingdata and a publication can be expected in the near future.Additionally, some of the results have been presented at the educational workshop.We expect to give more presentations at the scientific meetings for disseminating information.? What do you plan to do during the next reporting period to accomplish the goals?We plan to repeat part of the short-term studies because we found some results were not consistent and need to be confirmed by more data. If the animal facility could fully open, we plan to run the long-term studies.

    Impacts
    What was accomplished under these goals? A 6-week short term animal study with both genders has beencompleted to test how orange peel extracts ( polar and non-polar extracts) would affect gut microbiota composition and TMAO formation.Both TMA-lyase models (Cnt A/B and CUT C/D) were developed and purified. Many flavonoid compounds from orange peel were tested using this enzyme model.Polar and non-polar peel extracts were applied to this essay as well and will continue for the compounds isolation and purification.Levels of TMA, TMAO from both animal and enzyme models were tested using LC-MS/MS. Fecal samples has been extracted for the 16S rRNA. In addition, metabolites of orange peel in serum and urine were analyzed for additional information.

    Publications


      Progress 04/01/19 to 03/31/20

      Outputs
      Target Audience:Target audience of this project is citrus industry and the general public.Florida is the largest citrus producer in the U.S., with nearly 95% of Florida oranges used for juice. The current juice recovery rate is approximately fifty percent with the remaining peel byproduct typically going to cattle feed. Expanding the use of orange peel to benefit human health is a solid way to promote sustainability of US agriculture. Plus, this could potentially provide greater economic returns to the citrus industry.These scientific findings will be published in top journals such as Molecular Nutrition & Food Research, which possess a large number of readers from academia and industry. Additionally, these findings will be presented at scientific meetings for educating both industry and the public. The previous year was the first year to conduct this porject. We haven't reached a solid result/conslusion to report to the industry and the general public. Changes/Problems:1.3% carnitine in the diet might be an issue for us to get a consistent result. Therefore we deducted it to 0.6%. What opportunities for training and professional development has the project provided?We hired a postdoctoral associate in August 2019. This projectneeds analytical and molecular biology techniques. It is a good chance for the postdoc. trainee to learn both. This postdoc. submitted one abstract to a nutrition meeting but due to COVID-19, she didn't have a chance to present. How have the results been disseminated to communities of interest? Nothing Reported What do you plan to do during the next reporting period to accomplish the goals?We are conducting a longer-term animal study to understand effects of orange peel on improving gut health.In addition, we are using both metabolomics and bioactivity-guided isolation techniques to understand the effective compounds in orange peel.

      Impacts
      What was accomplished under these goals? A short-term treatment study was completed to test how orange peel affect TMAO formaton via microbiota. Six-week-old male C57BL/6J mice was used to examine the capability of gut microbiota to generate TMA and TMAO following carnitine intake, as well as the inhibitory efficacy of orange peel compared with the positive control, resveratrol and antibiotic cocktail.

      Publications